Project | ScopeScope |
This project team will define best practices for ensuring that similar types of adverse events are considered together for purposes of safety analyses. This project will develop efficient standardised processes and analyses that can leverage new technologies. |
Project Leads | Emails | ||
---|---|---|---|
Mac Gordon, Johnson & Johnson | Mary Nilsson | nilsson_mary_e@lilly.com | |
Peg Fletcher, MedAssessment | peg.fletcher@medassessment | Greg Ball | gball@novavax.com |
Objectives & Deliverables | |||
White Paper | |||
Journal Article | |||
Nicola Newton, PHUSE Project Assistant |
| ||||||
---|---|---|---|---|---|---|
New project for Q22022 | ||||||
Project Members | Organisation | |||||
Brian Panik | MedAssessment | |||||
Hannah Palac | AbbVie | |||||
Mac Gordon | Johnson & Jhonson | |||||
Nhi Beasley | FDA | |||||
Peg Fletcher | MedAssessment | |||||
Ramaiah Muvvala | Inductive Quotient | |||||
Rebeka Revis | IQVIA | |||||
Scott Proestel | FDA | Vaishali Popat | FDA||||
Q1 2024 | ||||||
|
Objectives & Deliverables | Timelines |
---|---|
Complete White Paper final draft | Q2 2023 |